SUNNYVALE, Calif., March 2, 2017 /PRNewswire/ -- The Internet
is one of the first places patients turn to for healthcare
information after receiving a cancer diagnosis, according to the
American Cancer Society. Accuray Incorporated (NASDAQ: ARAY) is
launching www.cyberknife.com and www.tomotherapy.com to provide an
additional resource for cancer patients to turn to for information
about their disease and potential treatment options. Enhanced
functionality and ease-of-use puts the information patients need at
their fingertips.
"Patients have told us they want concise information on
potential treatment options that is easy to understand, and they
want to hear from others who can share their real-world
experiences," said Susan Hopkins,
Chief Marketing Officer at Accuray. "We're committed to providing
cancer patients with educational tools and resources which will
enable them, in conversation with their physicians, to make the
treatment decisions that are right for them. We are launching these
new patient websites along with a major update to our Accuray.com
website as well."
The CyberKnife®, TomoTherapy® and Radixact™ Systems enable
physicians to deliver precise, non-invasive radiation treatment
options while minimizing side effects, helping to improve quality
of life. The product websites feature a variety of resources,
including:
- Overview of radiation therapy
- Step-by-step guide through the CyberKnife, TomoTherapy and
Radixact System treatment processes
- Location finder providing patients and caregivers with a
quick way to find the closest treatment center
- Patient narratives offering real-life, first-hand stories of
experiences being treated with the CyberKnife System and the
TomoTherapy System, including photos and videos
- Robust Resources sections with five key functions: Find
a Doctor, For Family & Friends, About Insurance, Glossary, and
Frequently Asked Questions
"Following successful treatment with the CyberKnife System for a
tumor on my spine, I gained a new perspective on life. I want to
help other people who, like me, are given a frightening diagnosis.
In addition to volunteering, I decided to share my story on
www.cyberknife.com," said Maria H. "The new website has the
information I would want as a patient considering treatment, and is
really easy to navigate. I feel good about sending people to the
site and hope my story inspires others who find themselves in a
similar situation."
By 2030, the global cancer incidence rate is projected to reach
25 millioni. Radiotherapy (RT) is a fundamental
component of oncology careii and an estimated 50% of
cancer patients would benefit from radiotherapy for treatment of
localized disease, local control, and palliation.iii
"When my doctor diagnosed me with multiple myeloma I remember
saying to myself, 'I refuse to die. I want to learn as much as I
can about my condition.' Coming to grips with cancer is difficult
but can be easier when advanced treatment options are identified.
The Internet is an important resource for information that can help
patients make a decision," said Carol R. "I recommend visiting the
new tomotherapy.com website. It's filled with information a
potential patient might need to help them, in discussion with their
doctor, to decide if it's the right treatment for them. The patient
stories, mine included, provide a real-world perspective on what to
expect from a TomoTherapy® treatment."
The Radixact™ Treatment Delivery System is the next generation
TomoTherapy platform, designed to enable doctors to more
efficiently and effectively deliver precise radiation treatments to
more patients. The system offers doctors the opportunity to improve
the cancer treatment experience throughout a patient's treatment
journey, including when retreatment is necessary.
About the CyberKnife®, TomoTherapy and Radixact™ Systems
The Accuray CyberKnife M6™ Series, TomoTherapy H™ Series and
Radixact treatment solutions cover the entire spectrum of radiation
therapy needs. The CyberKnife M6 Series enables precise,
high-quality, dose distributions to be confidently delivered to the
patient with extreme accuracy over a minimum number of treatments,
reducing side effects and preserving patients' quality of life. The
CyberKnife System is the only robotic full-body radiosurgery system
available today. The TomoTherapy H Series efficiently enables
physicians to customize treatment plans for the entire range of
radiation therapy patients and disease types. Its innovative design
enables treatment plans to be delivered with integrated, daily CT
image guidance, enhancing accuracy and delivering highly precise,
intensity-modulated radiation for optimal sparing of healthy tissue
and critical structures. The Radixact System empowers clinicians by
integrating treatment planning, data management and treatment
delivery. Using low-dose fan beam megavoltage x-ray radiation,
refined beamline and fast imaging technology, the system delivers
scalable and highly reliable treatment for patients with a variety
of treatment requirements.
Further information on Accuray and the CyberKnife, TomoTherapy
and Radixact Systems is available at www.accuray.com
Important Safety Information
For Important Safety Information please refer to
http://www.accuray.com/safety-statement-radiation-treatment
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company
that develops, manufactures and sells precise, innovative treatment
solutions that set the standard of care with the aim of helping
patients live longer, better lives. The company's leading-edge
technologies deliver the full range of radiation therapy and
radiosurgery treatments. For more information, please visit
www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient outcomes and Accuray's leadership
position in radiation oncology innovation and technologies.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from
expectations, including but not limited to the risks detailed from
time to time under the heading "Risk Factors" in the company's
report on Form 10-K, filed on August 24,
2016, the company's reports on Form 10-Q, filed on
November 1, 2016 and February 3, 2017, and as updated periodically
with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to
Accuray at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Jane Hauser
MSLGROUP
781-684-0770
accuray@mslgroup.com
i Ferlay J, Soerjomataram I, Dikshit R, et al.
Cancer incidence and mortality worldwide: sources, methods and
major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136:
E359-86.
ii Gunderston LLT, Joel E. Clinical Radiation
Oncology, 3rd edn. Philadelphia, PA: Elsevier, 2011.
iii Barton MB, Jacob S, Shafiq J, et al. Estimating the
demand for radiotherapy from the evidence: a review of changes from
2003 to 2012. Radiother Oncol 2014; 112: 140-44.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/accuray-launches-new-cancer-patient-websites-300416620.html
SOURCE Accuray Incorporated